Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDV tetravalent dengue vaccine in children aged 4-16 years
NCT02747927Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2016
- Primary completion
- Jul 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
A Phase 3 trial of live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus in dengue fever, sponsored by Takeda. Started Apr 2016; status: completed.
02
Drugs
live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02747927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02747927.